REVIEW ARTICLE
p267-287
Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay
Kevin Niswender
Abstract
Published Online: 6 Nov 2009
ORIGINAL ARTICLES
p288-298
Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature
L. Nalysnyk et al.
Abstract
Published Online: 22 Sep 2009
p299-306
Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551S. Fukuda, T. et al.
Abstract
Published Online: 22 Sep 2009
p307-315
Bioengineered skin in diabetic foot ulcers
Y. J. Teng et al.
Abstract
Published Online: 6 Nov 2009
p316-322
Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats
Y. Zhang et al.
Abstract
Published Online: 6 Nov 2009
p323-333
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus
K. Aaboe et al.
Abstract
Published Online: 6 Nov 2009
p334-340
Pharmacokinetics following continuous subcutaneous insulin infusion of insulin aspart with or without initial subcutaneous bolus
S. B. Petersen et al.
Abstract
Published Online: 6 Nov 2009
p341-347
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
K. Kaku et al.
Abstract
Published Online: 21 Dec 2009
p348-355
Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial
H. M. R. Pattzi et al.
Abstract
Published Online: 7 Jan 2010
RESEARCH LETTERS
p356-359
Metformin induces glucose uptake in human preadipocyte-derived adipocytes from various fat depots
M. Fischer et al.
Abstract
Published Online: 6 Nov 2009
p360-363
In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1K.
K.Kos et al.
Abstract
Published Online: 13 Nov 2009
This week's Diabetes Bulletin...
...
Showing posts with label Diabetes Obesity and Metabolism (journal). Show all posts
Showing posts with label Diabetes Obesity and Metabolism (journal). Show all posts
Monday, 15 March 2010
Wednesday, 17 February 2010
Diabetes, Obesity and Metabolism Vol 12 Iss 3 2010
REVIEW ARTICLES
p179-185
Oral insulin – a review of current status
Harish Iyer et al.
Abstract
Published Online: 22 Sep 2009
p186-194
Benefits of moderate weight loss in patients with type 2 diabetes
Ken Fujioka
Abstract
Published Online: 22 Sep 2009
ORIGINAL ARTICLES
p195-203
Selective effects of PPARγ agonists and antagonists on human pre-adipocyte differentiation
C. Leyvraz et al.
Abstract
Published Online: 5 Nov 2009
p204-209
A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study
A. Elhayany et al.
Abstract
Published Online: 22 Sep 2009
p210-218
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither
S. Conard et al.
Abstract
Published Online: 22 Sep 2009
p219-223
Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects
R. Eldor et al.
Abstract
Published Online: 22 Sep 2009
p224-233
Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice
Y. Moritoh et al.
Abstract
Published Online: 22 Sep 2009
p234-245
Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice
M. Perreault et al.
Abstract
Published Online: 22 Sep 2009
p246-251
Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study
K. Kondo, T. Kadowaki
Abstract
Published Online: 22 Sep 2009
p252-261
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
P. Aschner et al.
Abstract
Published Online: 25 Nov 2009
p179-185
Oral insulin – a review of current status
Harish Iyer et al.
Abstract
Published Online: 22 Sep 2009
p186-194
Benefits of moderate weight loss in patients with type 2 diabetes
Ken Fujioka
Abstract
Published Online: 22 Sep 2009
ORIGINAL ARTICLES
p195-203
Selective effects of PPARγ agonists and antagonists on human pre-adipocyte differentiation
C. Leyvraz et al.
Abstract
Published Online: 5 Nov 2009
p204-209
A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study
A. Elhayany et al.
Abstract
Published Online: 22 Sep 2009
p210-218
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither
S. Conard et al.
Abstract
Published Online: 22 Sep 2009
p219-223
Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects
R. Eldor et al.
Abstract
Published Online: 22 Sep 2009
p224-233
Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice
Y. Moritoh et al.
Abstract
Published Online: 22 Sep 2009
p234-245
Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice
M. Perreault et al.
Abstract
Published Online: 22 Sep 2009
p246-251
Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study
K. Kondo, T. Kadowaki
Abstract
Published Online: 22 Sep 2009
p252-261
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
P. Aschner et al.
Abstract
Published Online: 25 Nov 2009
Tuesday, 29 December 2009
Diabetes, Obesity and Metabolism Vol 12, Iss 2 2010
REVIEW ARTICLES
p91-96
Review of clinical trials: update on oral insulin spray formulation
Paolo Pozzilli et al.
Abstract
p97-104
Integrating educational and technological interventions to improve pregnancy outcomes in women with diabetes
Helen R. Murphy
Abstract
p105-114
Mid- and high-ratio premix insulin analogues: potential treatment options for patients with type 2 diabetes in need of greater postprandial blood glucose control
J. S. Christiansen et al.
Abstract
ORIGINAL ARTICLES
p115-123
Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes–results of the GINGER study
A. Fritsche et al.
Abstract
p124-132
Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones
D. R. Webb et al.
Abstract
p133-138
Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes
S. Mudaliar et al.
Abstract
p139-147
Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat
Z. Hassanali et al.
Abstract
p148-157
Multiple molecular targets underlie the antidiabetic effect of Nigella sativa seed extract in skeletal muscle, adipocyte and liver cells
A. Benhaddou-Andaloussi et al.
Abstract
p158-166
Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes
N. Perwitz et al.
Abstract
p167-177
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
T. Vilsbøll et al.
Abstract
p91-96
Review of clinical trials: update on oral insulin spray formulation
Paolo Pozzilli et al.
Abstract
p97-104
Integrating educational and technological interventions to improve pregnancy outcomes in women with diabetes
Helen R. Murphy
Abstract
p105-114
Mid- and high-ratio premix insulin analogues: potential treatment options for patients with type 2 diabetes in need of greater postprandial blood glucose control
J. S. Christiansen et al.
Abstract
ORIGINAL ARTICLES
p115-123
Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes–results of the GINGER study
A. Fritsche et al.
Abstract
p124-132
Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones
D. R. Webb et al.
Abstract
p133-138
Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes
S. Mudaliar et al.
Abstract
p139-147
Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat
Z. Hassanali et al.
Abstract
p148-157
Multiple molecular targets underlie the antidiabetic effect of Nigella sativa seed extract in skeletal muscle, adipocyte and liver cells
A. Benhaddou-Andaloussi et al.
Abstract
p158-166
Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes
N. Perwitz et al.
Abstract
p167-177
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
T. Vilsbøll et al.
Abstract
Diabetes, Obesity and Metabolism Vol 12, Iss 1 2010
REVIEW ARTICLES
p1-11
Future perspectives for insulinotropic agents in the treatment of type 2 diabetes–DPP-4 inhibitors and sulphonylureas
B. Gallwitz, H.-U. Häring
Abstract
p12-19
How can structured self-management patient education improve outcomes in people with type 2 diabetes?
J. Jarvis et al.
Abstract
p20-25
Managing women with gestational diabetes mellitus in the postnatal period
Catherine Kim
Abstract
ORIGINAL ARTICLES
p26-34
Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial
L. F. Van Gaal et al.
Abstract
p35-46
Sterol regulatory element-binding protein-1c knockdown protected INS-1E cells from lipotoxicity
J. Li et al.
Abstract
p47-53
Insulin use and increased risk of mortality in type 2 diabetes: a cohort study
J.-M. Gamble et al.
Abstract
p54-64
Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting
C. McAdam-Marx et al.
Abstract
p65-71
The response to short-term intensive insulin therapy in type 2 diabetes
R. Retnakaran et al.
Abstract
p72-81
The effects of Xanthigen™ in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat
M. Abidov et al.
Abstract
p82-87
The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes
S. D. Luzio et al.
Abstract
p1-11
Future perspectives for insulinotropic agents in the treatment of type 2 diabetes–DPP-4 inhibitors and sulphonylureas
B. Gallwitz, H.-U. Häring
Abstract
p12-19
How can structured self-management patient education improve outcomes in people with type 2 diabetes?
J. Jarvis et al.
Abstract
p20-25
Managing women with gestational diabetes mellitus in the postnatal period
Catherine Kim
Abstract
ORIGINAL ARTICLES
p26-34
Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial
L. F. Van Gaal et al.
Abstract
p35-46
Sterol regulatory element-binding protein-1c knockdown protected INS-1E cells from lipotoxicity
J. Li et al.
Abstract
p47-53
Insulin use and increased risk of mortality in type 2 diabetes: a cohort study
J.-M. Gamble et al.
Abstract
p54-64
Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting
C. McAdam-Marx et al.
Abstract
p65-71
The response to short-term intensive insulin therapy in type 2 diabetes
R. Retnakaran et al.
Abstract
p72-81
The effects of Xanthigen™ in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat
M. Abidov et al.
Abstract
p82-87
The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes
S. D. Luzio et al.
Abstract
Tuesday, 10 November 2009
Diabetes, Obesity and Metabolism, Vol 11, Iss 3 2009
Editorial
p1-3
The clinical challenges of managing type 2 diabetes and the potential of GLP-1-based therapies
Bernard Zinman
Abstract
Published Online: 29 Oct 2009
Original Articles
p4-10
Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes
G. Sesti
Abstract
Published Online: 29 Oct 2009
p11-18
The effects of glucagon-like peptide-1 on the beta cell
T. Vilsbøll
Abstract
Published Online: 29 Oct 2009
p19-25
Impact of glucagon-like peptide-1 on endothelial function
Å Sjöholm
Abstract
Published Online: 29 Oct 2009
p26-34
The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies
L. Blonde, D. Russell-Jones
Abstract
Published Online: 29 Oct 2009
p1-3
The clinical challenges of managing type 2 diabetes and the potential of GLP-1-based therapies
Bernard Zinman
Abstract
Published Online: 29 Oct 2009
Original Articles
p4-10
Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes
G. Sesti
Abstract
Published Online: 29 Oct 2009
p11-18
The effects of glucagon-like peptide-1 on the beta cell
T. Vilsbøll
Abstract
Published Online: 29 Oct 2009
p19-25
Impact of glucagon-like peptide-1 on endothelial function
Å Sjöholm
Abstract
Published Online: 29 Oct 2009
p26-34
The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies
L. Blonde, D. Russell-Jones
Abstract
Published Online: 29 Oct 2009
Monday, 19 October 2009
Diabetes, Obesity and Metabolism Vol 11, Iss 11 2009
N.B. We do not have full text access to this title
Review Article
p 997-1000
Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus
Naveed Younis et al.
Abstract
Published Online: Jun 16 2009
Original Articles
p 1001-1008
A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion
A. Liebl et al.
Abstract
Published Online: Sep 9 2009
p 1009-1016
Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone
R. Chapell et al.
Abstract
Published Online: Jul 13 2009
p 1017-1026
Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin
O. Tschritter et al.
Abstract
Published Online: Jul 23 2009
p 1027-1033
Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery
M. Guldstrand et al.
Abstract
Published Online: Jul 13 2009
p 1034-1049
Dietary supplementation of tetradecylthioacetic acid increases feed intake but reduces body weight gain and adipose depot sizes in rats fed on high-fat diets
A. J. Wensaas et al.
Abstract
Published Online: Sep 9 2009
p 1050-1059
Evaluation of novel particles as an inhalation system for GLP-1
A. Leone-Bay et al.
Abstract
Published Online: Sep 3 2009
p 1060-1067
The PPAR- agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation
H. Kilter et al.
Abstract
Published Online: Sep 3 2009
p 1068-1079
Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting
T. Mittendorf et al.
Abstract
Published Online: Sep 3 2009
Research Letters
p 1080-1083
Interaction of beta-blockers with the renal uptake transporter OCT2
I. Bachmakov et al.
Abstract
Published Online: Sep 9 2009
p 1084-1087
Protein kinase C beta inhibitor prevents diabetic peripheral neuropathy, but not histopathological abnormalities of retina in Spontaneously Diabetic Torii rat
T. Sasase et al.
Abstract
Published Online: Jul 13 2009
Review Article
p 997-1000
Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus
Naveed Younis et al.
Abstract
Published Online: Jun 16 2009
Original Articles
p 1001-1008
A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion
A. Liebl et al.
Abstract
Published Online: Sep 9 2009
p 1009-1016
Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone
R. Chapell et al.
Abstract
Published Online: Jul 13 2009
p 1017-1026
Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin
O. Tschritter et al.
Abstract
Published Online: Jul 23 2009
p 1027-1033
Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery
M. Guldstrand et al.
Abstract
Published Online: Jul 13 2009
p 1034-1049
Dietary supplementation of tetradecylthioacetic acid increases feed intake but reduces body weight gain and adipose depot sizes in rats fed on high-fat diets
A. J. Wensaas et al.
Abstract
Published Online: Sep 9 2009
p 1050-1059
Evaluation of novel particles as an inhalation system for GLP-1
A. Leone-Bay et al.
Abstract
Published Online: Sep 3 2009
p 1060-1067
The PPAR- agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation
H. Kilter et al.
Abstract
Published Online: Sep 3 2009
p 1068-1079
Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting
T. Mittendorf et al.
Abstract
Published Online: Sep 3 2009
Research Letters
p 1080-1083
Interaction of beta-blockers with the renal uptake transporter OCT2
I. Bachmakov et al.
Abstract
Published Online: Sep 9 2009
p 1084-1087
Protein kinase C beta inhibitor prevents diabetic peripheral neuropathy, but not histopathological abnormalities of retina in Spontaneously Diabetic Torii rat
T. Sasase et al.
Abstract
Published Online: Jul 13 2009
Diabetes, Obesity and Metabolism, Vol 11, Iss 10 2009
N.B. We do not have full text access to this title
Review Articles
p 913-930
Home telehealth for diabetes management:
a systematic review and meta-analysis
J. Polisena et al.
Abstract
Published Online: June 16 2009
p 931-938
Strategies to prevent type 1 diabetes
S. L. Thrower et al.
Abstract
Published Online: May 19 2009
Original Articles
p 939-946
Exendin-4 regulates glucokinase expression by CaMKK/CaMKIV pathway in pancreatic -cell line
K. Murao et al.
Abstract
Published Online: May 26 2009
p 947-952
Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control
P. Raskin et al.
Abstract
Published Online: Jun 16 2009
p 953-965
Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation
X. Ma et al.
Abstract
Published Online: Jun 16 2009
p 966-977
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes
S. S. Lund et al.
Abstract
Published Online: Jun 25 2009
p 978-986
Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial – a primary care, type 2 diabetes study
L. Blonde et al.
Abstract
Published Online: Jul 13 2009
Research Letters
p 987-991
Soraphen, an inhibitor of the acetyl-CoA carboxylase system, improves peripheral insulin sensitivity in mice fed a high-fat diet
M. Schreurs et al.
Abstract
Published Online: Jun 10 2009
p 992-995
An NMR-based metabonomic investigation on effects of supplementation with isosteviol or soy protein to diabetic KKAy mice
H. C. Bertram et al.
Abstract
Published Online: Jun 25 2009
Review Articles
p 913-930
Home telehealth for diabetes management:
a systematic review and meta-analysis
J. Polisena et al.
Abstract
Published Online: June 16 2009
p 931-938
Strategies to prevent type 1 diabetes
S. L. Thrower et al.
Abstract
Published Online: May 19 2009
Original Articles
p 939-946
Exendin-4 regulates glucokinase expression by CaMKK/CaMKIV pathway in pancreatic -cell line
K. Murao et al.
Abstract
Published Online: May 26 2009
p 947-952
Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control
P. Raskin et al.
Abstract
Published Online: Jun 16 2009
p 953-965
Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation
X. Ma et al.
Abstract
Published Online: Jun 16 2009
p 966-977
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes
S. S. Lund et al.
Abstract
Published Online: Jun 25 2009
p 978-986
Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial – a primary care, type 2 diabetes study
L. Blonde et al.
Abstract
Published Online: Jul 13 2009
Research Letters
p 987-991
Soraphen, an inhibitor of the acetyl-CoA carboxylase system, improves peripheral insulin sensitivity in mice fed a high-fat diet
M. Schreurs et al.
Abstract
Published Online: Jun 10 2009
p 992-995
An NMR-based metabonomic investigation on effects of supplementation with isosteviol or soy protein to diabetic KKAy mice
H. C. Bertram et al.
Abstract
Published Online: Jun 25 2009
Wednesday, 14 October 2009
Diabetes, Obesity and Metabolism, Vol 11, Special Issue 2009
N.B. We do not have full text access to this title
Preface
p iii-iv
Perspectives in type 2 diabetes: incorporating the latest insulin analogue strategies to achieve treatment success
Abstract
Published Online: 7 Oct 2009
Introduction
p 1-5
Restaging insulin therapy for patients with type 2 diabetes
A. J. Garber
Abstract
Published Online: 7 Oct 2009
Review Articles
p 6-9
Starting insulin strategies for patients with an inadequate response to oral therapy
A. R. Rolla
Abstract
Published Online: 7 Oct 2009
p 10-13
The importance of titrating starting insulin regimens in patients with type 2 diabetes
A. J. Garber
Abstract
Published Online: 7 Oct 2009
p 14-18
Insulin intensification strategies in type 2 diabetes: when one injection is no longer sufficient
A. J. Garber
Abstract
Published Online: 7 Oct 2009
p 19-22
What about insulin as an immediate first step for type 2 diabetes?
A. R. Rolla
Abstract
Published Online: 7 Oct 2009
Preface
p iii-iv
Perspectives in type 2 diabetes: incorporating the latest insulin analogue strategies to achieve treatment success
Abstract
Published Online: 7 Oct 2009
Introduction
p 1-5
Restaging insulin therapy for patients with type 2 diabetes
A. J. Garber
Abstract
Published Online: 7 Oct 2009
Review Articles
p 6-9
Starting insulin strategies for patients with an inadequate response to oral therapy
A. R. Rolla
Abstract
Published Online: 7 Oct 2009
p 10-13
The importance of titrating starting insulin regimens in patients with type 2 diabetes
A. J. Garber
Abstract
Published Online: 7 Oct 2009
p 14-18
Insulin intensification strategies in type 2 diabetes: when one injection is no longer sufficient
A. J. Garber
Abstract
Published Online: 7 Oct 2009
p 19-22
What about insulin as an immediate first step for type 2 diabetes?
A. R. Rolla
Abstract
Published Online: 7 Oct 2009
Monday, 12 October 2009
Diabetes, Obesity and Metabolism, Vol 11, Iss 9 2009
N.B. We do not have full text access to this title
p 823-835
Ammonia toxicity and its prevention in inherited defects of the urea cycle
V. Walker
Abstract
Published Online: 16 Jun 2009
p 836-843
Improved cardiovascular health following a progressive walking and dietary intervention for type 2 diabetes
S. T. Johnson et al.
Abstract
Published Online: 10 Jul 2009
p 844-854
Earlier triple therapy with pioglitazone in patients with type 2 diabetes
G. Charpentier, S. Halimi
Abstract
Published Online: 13 Jul 2009
p 855-864
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia
J. E. Tomassini et al.
Abstract
Published Online: 5 Jun 2009
p 865-873
Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet
P. Raskin et al.
Abstract
Published Online: 19 May 2009
p 874-883
Maximal lipid oxidation in patients with type 2 diabetes is normal and shows an adequate increase in response to aerobic training
M. Mogensen et al.
Abstract
Published Online: 16 Jun 2009
p 884-890
Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto–Kakizaki rats
L. Simonsen et al.
Abstract
Published Online: 5 Jun 2009
p 891-899
Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus
R. Kawamori et al.
Abstract
Published Online: 13 Jul 2009
p 900-909
Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus
R. Kawamori et al.
Abstract
Published Online: 13 Jul 2009
p 823-835
Ammonia toxicity and its prevention in inherited defects of the urea cycle
V. Walker
Abstract
Published Online: 16 Jun 2009
p 836-843
Improved cardiovascular health following a progressive walking and dietary intervention for type 2 diabetes
S. T. Johnson et al.
Abstract
Published Online: 10 Jul 2009
p 844-854
Earlier triple therapy with pioglitazone in patients with type 2 diabetes
G. Charpentier, S. Halimi
Abstract
Published Online: 13 Jul 2009
p 855-864
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia
J. E. Tomassini et al.
Abstract
Published Online: 5 Jun 2009
p 865-873
Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet
P. Raskin et al.
Abstract
Published Online: 19 May 2009
p 874-883
Maximal lipid oxidation in patients with type 2 diabetes is normal and shows an adequate increase in response to aerobic training
M. Mogensen et al.
Abstract
Published Online: 16 Jun 2009
p 884-890
Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto–Kakizaki rats
L. Simonsen et al.
Abstract
Published Online: 5 Jun 2009
p 891-899
Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus
R. Kawamori et al.
Abstract
Published Online: 13 Jul 2009
p 900-909
Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus
R. Kawamori et al.
Abstract
Published Online: 13 Jul 2009
Friday, 24 April 2009
Diabetes, Obesity and Metabolism Vol. 11, Supplement 2
We do not have full text access to this journal. Please contact the library to order articles via interlibrary loan.
Islet Enhancer Vildagliptin: A Powerful Partner with Metformin for the Treatment of Patients with Type 2 Diabetes
The publication of this supplement was supported by Novartis Pharma AG
Introduction
1-2
Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes
W. A Scherbaum
Abstract
Published Online: 17 Apr 2009
DOI 10.1111/j.1463-1326.2008.01032.x
Review Articles
3-8
Metformin – the gold standard in type 2 diabetes: what does the evidence tell us?
E. Bosi
Abstract
Published Online: 17 Apr 2009
DOI 10.1111/j.1463-1326.2008.01031.x
9-17
The scientific evidence: vildagliptin and the benefits of islet enhancement
C. Mathieu
Abstract
Published Online: 17 Apr 2009
DOI 10.1111/j.1463-1326.2008.01033.x
18-26
Translating science into clinical practice: focus on vildagliptin in combination with metformin
A. H. Barnett
Abstract
Published Online: 17 Apr 2009
DOI 10.1111/j.1463-1326.2008.01030.x
Islet Enhancer Vildagliptin: A Powerful Partner with Metformin for the Treatment of Patients with Type 2 Diabetes
The publication of this supplement was supported by Novartis Pharma AG
Introduction
1-2
Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes
W. A Scherbaum
Abstract
Published Online: 17 Apr 2009
DOI 10.1111/j.1463-1326.2008.01032.x
Review Articles
3-8
Metformin – the gold standard in type 2 diabetes: what does the evidence tell us?
E. Bosi
Abstract
Published Online: 17 Apr 2009
DOI 10.1111/j.1463-1326.2008.01031.x
9-17
The scientific evidence: vildagliptin and the benefits of islet enhancement
C. Mathieu
Abstract
Published Online: 17 Apr 2009
DOI 10.1111/j.1463-1326.2008.01033.x
18-26
Translating science into clinical practice: focus on vildagliptin in combination with metformin
A. H. Barnett
Abstract
Published Online: 17 Apr 2009
DOI 10.1111/j.1463-1326.2008.01030.x
Diabetes, Obesity and Metabolism Vol. 11, Iss. 5
We do not have full text access to this journal. Please contcat the library to order copies of articles.
Review Articles
407-414
The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies
Mark W. J. Strachan, Rebecca M. Reynolds, Brian M. Frier, Rory J. Mitchell, Jacqueline F. Price
Abstract
Published Online: 15 Apr 2009
DOI 10.1111/j.1463-1326.2008.00963.x
415-432
Insulin therapy in type 2 diabetes: what is the evidence?
Mariëlle J. P. van Avendonk, Guy E. H. M Rutten
Abstract
Published Online:
19 Jan 2009
DOI 10.1111/j.1463-1326.2008.00981.x
433-444
Treatment of diabetic hypertension
David S. H. Bell
Abstract
Published Online: 18 Feb 2009
DOI 10.1111/j.1463-1326.2008.00983.x
445-454
Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome
F. Montecucco, F. Mach
Abstract
Published Online: 10 Feb 2009
DOI 10.1111/j.1463-1326.2008.00986.x
Original Articles
455-459
PROMAXX® inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler
T. Heise, A. Brugger, C. Cook, U. Eckers, A. Hutchcraft, L. Nosek, K. Rave, J. Troeger, P. Valaitis, S. White, L. Heinemann
Abstract
Published Online: 19 Feb 2009
DOI 10.1111/j.1463-1326.2008.00961.x
460-463
Lipohypertrophy: does it matter in daily life? A study using a continuous glucose monitoring system
J. Overland, L. Molyneaux, S. Tewari, R. Fatouros, P. Melville, D. Foote, T. Wu, D. K. Yue
Abstract
Published Online: 18 Feb 2009
DOI 10.1111/j.1463-1326.2008.00972.x
464-471
Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β-cell function: results from the PioSwitch Study
C. Hohberg, A. Pfützner, T. Forst, G. Lübben, E. Karagiannis, M. Borchert, T. Schöndorf
Abstract
Published Online: 15 Apr 2009
DOI 10.1111/j.1463-1326.2008.00975.x
472-479
Biomarkers of body iron stores and risk of developing type 2 diabetes
S. N. Rajpathak, J. Wylie-Rosett, M. J. Gunter, A. Negassa, G. C. Kabat, T. E. Rohan, J. Crandall
Abstract
Published Online: 21 Jan 2009
DOI 10.1111/j.1463-1326.2008.00985.x
480-490
Antioxidants attenuate hyperglycaemia-mediated brain endothelial cell dysfunction and blood–brain barrier hyperpermeability
C. L. Allen, U. Bayraktutan
Abstract
Published Online: 18 Feb 2009
DOI 10.1111/j.1463-1326.2008.00987.x
491-497
Treatment choice and effectiveness of adding sulphonylurea or glitazones to metformin for the treatment of type 2 diabetes mellitus
T. Stargardt, D. D. Yin, C. M. Alexander
Abstract
Published Online: 18 Feb 2009
DOI 10.1111/j.1463-1326.2008.00991.x
498-505
Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
M. A. Bush, J. E. Matthews, E. H. De Boever, R. L. Dobbins, R. J. Hodge, S. E. Walker, M. C. Holland, M. Gutierrez, M. W. Stewart
Abstract
Published Online: 2 Feb 2009
DOI 10.1111/j.1463-1326.2008.00992.x
506-515
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
E. Bosi, F Dotta, Y Jia, M Goodman
Abstract
Published Online: 23 Mar 2009
DOI 10.1111/j.1463-1326.2009.01040.x
Research Letters
516-518
Reproducibility of hepatic triglyceride content assessment in normals using localized magnetic resonance spectroscopy
J. Kullberg, F. Ortiz-Nieto, L. Johansson
Abstract
Published Online: 15 Apr 2009
DOI 10.1111/j.1463-1326.2008.00979.x
519-522
Rosiglitazone protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression
Xin-ming Yao, Shan-dong Ye, Yan Chen, Zhi-ming Zai, Xiu-cai Li, Ying-xin Wang, Ke Chen
Abstract
Published Online: 18 Feb 2009
DOI 10.1111/j.1463-1326.2008.00990.x
News and Views
523-525
News and Views
Iskandar Idris
Abstract
Published Online: 15 Apr 2009
DOI 10.1111/j.1463-1326.2009.01065.x
Review Articles
407-414
The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies
Mark W. J. Strachan, Rebecca M. Reynolds, Brian M. Frier, Rory J. Mitchell, Jacqueline F. Price
Abstract
Published Online: 15 Apr 2009
DOI 10.1111/j.1463-1326.2008.00963.x
415-432
Insulin therapy in type 2 diabetes: what is the evidence?
Mariëlle J. P. van Avendonk, Guy E. H. M Rutten
Abstract
Published Online:
19 Jan 2009
DOI 10.1111/j.1463-1326.2008.00981.x
433-444
Treatment of diabetic hypertension
David S. H. Bell
Abstract
Published Online: 18 Feb 2009
DOI 10.1111/j.1463-1326.2008.00983.x
445-454
Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome
F. Montecucco, F. Mach
Abstract
Published Online: 10 Feb 2009
DOI 10.1111/j.1463-1326.2008.00986.x
Original Articles
455-459
PROMAXX® inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler
T. Heise, A. Brugger, C. Cook, U. Eckers, A. Hutchcraft, L. Nosek, K. Rave, J. Troeger, P. Valaitis, S. White, L. Heinemann
Abstract
Published Online: 19 Feb 2009
DOI 10.1111/j.1463-1326.2008.00961.x
460-463
Lipohypertrophy: does it matter in daily life? A study using a continuous glucose monitoring system
J. Overland, L. Molyneaux, S. Tewari, R. Fatouros, P. Melville, D. Foote, T. Wu, D. K. Yue
Abstract
Published Online: 18 Feb 2009
DOI 10.1111/j.1463-1326.2008.00972.x
464-471
Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β-cell function: results from the PioSwitch Study
C. Hohberg, A. Pfützner, T. Forst, G. Lübben, E. Karagiannis, M. Borchert, T. Schöndorf
Abstract
Published Online: 15 Apr 2009
DOI 10.1111/j.1463-1326.2008.00975.x
472-479
Biomarkers of body iron stores and risk of developing type 2 diabetes
S. N. Rajpathak, J. Wylie-Rosett, M. J. Gunter, A. Negassa, G. C. Kabat, T. E. Rohan, J. Crandall
Abstract
Published Online: 21 Jan 2009
DOI 10.1111/j.1463-1326.2008.00985.x
480-490
Antioxidants attenuate hyperglycaemia-mediated brain endothelial cell dysfunction and blood–brain barrier hyperpermeability
C. L. Allen, U. Bayraktutan
Abstract
Published Online: 18 Feb 2009
DOI 10.1111/j.1463-1326.2008.00987.x
491-497
Treatment choice and effectiveness of adding sulphonylurea or glitazones to metformin for the treatment of type 2 diabetes mellitus
T. Stargardt, D. D. Yin, C. M. Alexander
Abstract
Published Online: 18 Feb 2009
DOI 10.1111/j.1463-1326.2008.00991.x
498-505
Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
M. A. Bush, J. E. Matthews, E. H. De Boever, R. L. Dobbins, R. J. Hodge, S. E. Walker, M. C. Holland, M. Gutierrez, M. W. Stewart
Abstract
Published Online: 2 Feb 2009
DOI 10.1111/j.1463-1326.2008.00992.x
506-515
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
E. Bosi, F Dotta, Y Jia, M Goodman
Abstract
Published Online: 23 Mar 2009
DOI 10.1111/j.1463-1326.2009.01040.x
Research Letters
516-518
Reproducibility of hepatic triglyceride content assessment in normals using localized magnetic resonance spectroscopy
J. Kullberg, F. Ortiz-Nieto, L. Johansson
Abstract
Published Online: 15 Apr 2009
DOI 10.1111/j.1463-1326.2008.00979.x
519-522
Rosiglitazone protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression
Xin-ming Yao, Shan-dong Ye, Yan Chen, Zhi-ming Zai, Xiu-cai Li, Ying-xin Wang, Ke Chen
Abstract
Published Online: 18 Feb 2009
DOI 10.1111/j.1463-1326.2008.00990.x
News and Views
523-525
News and Views
Iskandar Idris
Abstract
Published Online: 15 Apr 2009
DOI 10.1111/j.1463-1326.2009.01065.x
Friday, 13 March 2009
Diabetes, Obesity and Metabolism Volume11, Issue4, 2009
We do not have full text access to this journal. Please contact the library to order articles via interlibrary loan.
Review Article
275-284
Thiazolidinedione-induced skeletal fragility – mechanisms and implications
Andrew Grey
Abstract
Published Online: 30 Jul 2008
DOI 10.1111/j.1463-1326.2008.00931.x
Original Articles
285-292
DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue
K. Kos, A. R. Baker, M. Jernas, A. L. Harte, J. C. Clapham, J. P. O'Hare, L. Carlsson, S. Kumar, P. G. McTernan
Abstract
Published Online: 19 Jan 2009
DOI 10.1111/j.1463-1326.2008.00909.x
293-303
Chromium supplementation enhances insulin signalling in skeletal muscle of obese KK/HlJ diabetic mice
W.-Y. Chen, C.-J. Chen, C.-H. Liu, F. C. Mao
Abstract
Published Online: 20 Aug 2008
DOI 10.1111/j.1463-1326.2008.00936.x
304-314
Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-α/δ activation and increased mitochondrial fatty acid oxidation
K. Løvås, T. H. Røst, J. Skorve, R. J. Ulvik, O. A. Gudbrandsen, P. Bohov, A. J. Wensaas, A. C. Rustan, R. K. Berge, E. S. Husebye
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00958.x
315-322
Study rationale and design of the CIMT trial: The Copenhagen Insulin and Metformin Therapy Trial
L. Lundby Christensen, T. Almdal, T. Boesgaard, L. Breum, E. Dunn, B. Gade-Rasmussen, C. Gluud, C. Hedetoft, A. Jarloev, T. Jensen, T. Krarup, L. B. Johansen, S. S. Lund, S. Madsbad, E. Mathiesen, J. Moelvig, F. Nielsen, H. Perrild, O. Pedersen, M. Roeder, S. B. Sneppen, O. Snorgaard, L. Tarnow, B. Thorsteinsson, A. Vaag, H. Vestergaard, J. Wetterslev, N. Wiinberg
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00959.x
323-329
Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study
A.-M. Aas, J. Öhrvik, K. Malmberg, L. Rydén, K. I. Birkeland
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00964.x
330-337
Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome
A. K. Gupta, S. R. Smith, F. L. Greenway, G. A. Bray
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00965.x
338-342
Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study
L. A. Donnelly, A. D. Morris, E. R. Pearson
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00973.x
343-354
Diet-induced adiposity alters the serum profile of inflammation in C57BL/6N mice as measured by antibody array
J. I. Fenton, N. P. Nuñez, S. Yakar, S. N. Perkins, N. G. Hord, S. D. Hursting
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00974.x
355-360
Improved glycaemic control decreases inner mitochondrial membrane leak in type 2 diabetes
R. Rabøl, P. M. V. Højberg, T. Almdal, R. Boushel, S. B. Haugaard, S. Madsbad, F. Dela
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00977.x
361-371
Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss
S. Jacob, M. Rabbia, M. K. Meier, J. Hauptman
Abstract
Published Online: 22 Jan 2009
DOI 10.1111/j.1463-1326.2008.00970.x
372-378
Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis
M. Monami, N. Marchionni, E. Mannucci
Abstract
Published Online: 13 Oct 2008DOI 10.1111/j.1463-1326.2008.00976.x
379-386
Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7–8% A1c levels. The TULIP study
J-F. Blicklé, N. Hancu, M. Piletic, V. Profozic, M. Shestakova, M-P. Dain, S. Jacqueminet, A. Grimaldi
Abstract
Published Online: 14 Dec 2008
DOI 10.1111/j.1463-1326.2008.00980.x
387-396
A low-GI diet is associated with a short-term improvement of glycaemic control in Asian patients with type 2 diabetes
B. N. M. Yusof, R. A. Talib, N. A. Kamaruddin, N. A. Karim, K. Chinna, H. Gilbertson
Abstract
Published Online: 19 Jan 2009
DOI 10.1111/j.1463-1326.2008.00984.x
Research Letter
397-404
Effects of elevated fatty acid and glucose concentrations on pancreatic islet function in vitro
J. Hong, P. B. Jeppesen, K. Hermansen
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00971.x
Erratum
405-405
Erratum
Abstract
Published Online: 24 Feb 2009
DOI 10.1111/j.1463-1326.2009.01047.x
Review Article
275-284
Thiazolidinedione-induced skeletal fragility – mechanisms and implications
Andrew Grey
Abstract
Published Online: 30 Jul 2008
DOI 10.1111/j.1463-1326.2008.00931.x
Original Articles
285-292
DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue
K. Kos, A. R. Baker, M. Jernas, A. L. Harte, J. C. Clapham, J. P. O'Hare, L. Carlsson, S. Kumar, P. G. McTernan
Abstract
Published Online: 19 Jan 2009
DOI 10.1111/j.1463-1326.2008.00909.x
293-303
Chromium supplementation enhances insulin signalling in skeletal muscle of obese KK/HlJ diabetic mice
W.-Y. Chen, C.-J. Chen, C.-H. Liu, F. C. Mao
Abstract
Published Online: 20 Aug 2008
DOI 10.1111/j.1463-1326.2008.00936.x
304-314
Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-α/δ activation and increased mitochondrial fatty acid oxidation
K. Løvås, T. H. Røst, J. Skorve, R. J. Ulvik, O. A. Gudbrandsen, P. Bohov, A. J. Wensaas, A. C. Rustan, R. K. Berge, E. S. Husebye
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00958.x
315-322
Study rationale and design of the CIMT trial: The Copenhagen Insulin and Metformin Therapy Trial
L. Lundby Christensen, T. Almdal, T. Boesgaard, L. Breum, E. Dunn, B. Gade-Rasmussen, C. Gluud, C. Hedetoft, A. Jarloev, T. Jensen, T. Krarup, L. B. Johansen, S. S. Lund, S. Madsbad, E. Mathiesen, J. Moelvig, F. Nielsen, H. Perrild, O. Pedersen, M. Roeder, S. B. Sneppen, O. Snorgaard, L. Tarnow, B. Thorsteinsson, A. Vaag, H. Vestergaard, J. Wetterslev, N. Wiinberg
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00959.x
323-329
Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study
A.-M. Aas, J. Öhrvik, K. Malmberg, L. Rydén, K. I. Birkeland
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00964.x
330-337
Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome
A. K. Gupta, S. R. Smith, F. L. Greenway, G. A. Bray
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00965.x
338-342
Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study
L. A. Donnelly, A. D. Morris, E. R. Pearson
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00973.x
343-354
Diet-induced adiposity alters the serum profile of inflammation in C57BL/6N mice as measured by antibody array
J. I. Fenton, N. P. Nuñez, S. Yakar, S. N. Perkins, N. G. Hord, S. D. Hursting
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00974.x
355-360
Improved glycaemic control decreases inner mitochondrial membrane leak in type 2 diabetes
R. Rabøl, P. M. V. Højberg, T. Almdal, R. Boushel, S. B. Haugaard, S. Madsbad, F. Dela
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00977.x
361-371
Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss
S. Jacob, M. Rabbia, M. K. Meier, J. Hauptman
Abstract
Published Online: 22 Jan 2009
DOI 10.1111/j.1463-1326.2008.00970.x
372-378
Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis
M. Monami, N. Marchionni, E. Mannucci
Abstract
Published Online: 13 Oct 2008DOI 10.1111/j.1463-1326.2008.00976.x
379-386
Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7–8% A1c levels. The TULIP study
J-F. Blicklé, N. Hancu, M. Piletic, V. Profozic, M. Shestakova, M-P. Dain, S. Jacqueminet, A. Grimaldi
Abstract
Published Online: 14 Dec 2008
DOI 10.1111/j.1463-1326.2008.00980.x
387-396
A low-GI diet is associated with a short-term improvement of glycaemic control in Asian patients with type 2 diabetes
B. N. M. Yusof, R. A. Talib, N. A. Kamaruddin, N. A. Karim, K. Chinna, H. Gilbertson
Abstract
Published Online: 19 Jan 2009
DOI 10.1111/j.1463-1326.2008.00984.x
Research Letter
397-404
Effects of elevated fatty acid and glucose concentrations on pancreatic islet function in vitro
J. Hong, P. B. Jeppesen, K. Hermansen
Abstract
Published Online: 13 Oct 2008
DOI 10.1111/j.1463-1326.2008.00971.x
Erratum
405-405
Erratum
Abstract
Published Online: 24 Feb 2009
DOI 10.1111/j.1463-1326.2009.01047.x
Friday, 7 November 2008
Diabetes, Obesity and Metabolism Vol. 10, Iss. 12, 2008.
We do not have full text access to this journal. Please contact the library to order articles via interlibrary loan.
Pages: 1135-1156
Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women
Szalat Auryan, Raz Itamar
http://www3.interscience.wiley.com/cgi-bin/abstract/120125640/ABSTRACT
Pages: 1157-1166
The role of renin–angiotensin–aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection
Hussam Abuissa, James O'Keefe Jr
http://www3.interscience.wiley.com/cgi-bin/abstract/120125642/ABSTRACT
Pages: 1167-1177
Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes
P. Raskin
http://www3.interscience.wiley.com/cgi-bin/abstract/120125648/ABSTRACT
Pages: 1178-1185
Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs
M. R. Lankisch, K. C. Ferlinz, J. L. Leahy, W. A. Scherbaum
http://www3.interscience.wiley.com/cgi-bin/abstract/121494348/ABSTRACT
Pages: 1186-1194
Persistence of improvement in insulin sensitivity following a dietary weight loss programme
T. McLaughlin, P. Schweitzer, S. Carter, C.-G. Yen, C. Lamendola, F. Abbasi, G. Reaven
http://www3.interscience.wiley.com/cgi-bin/abstract/120125630/ABSTRACT
Pages: 1195-1203
Weight loss in obese men by caloric restriction and high-dose diazoxide–mediated insulin suppression
G. van Boekel, S. Loves, A. van Sorge, J. Ruinemans-Koerts, T. Rijnders, H. de Boer
http://www3.interscience.wiley.com/cgi-bin/abstract/120125631/ABSTRACT
Pages: 1204-1211
Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients
Y. Miyazaki, R. A. DeFronzo
http://www3.interscience.wiley.com/cgi-bin/abstract/120125633/ABSTRACT
Pages: 1212-1220
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach
L. Xu, C. Dalla Man, B. Charbonnel, G. Meninger, M. J. Davies, D. Williams-Herman, C. Cobelli, P. P. Stein
http://www3.interscience.wiley.com/cgi-bin/abstract/120125634/ABSTRACT
Pages: 1221-1238
Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials
E. Mannucci, M. Monami, C. Lamanna, G. F. Gensini, N. Marchionni
http://www3.interscience.wiley.com/cgi-bin/abstract/120125638/ABSTRACT
Pages: 1239-1247
The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release–based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study)
A. H. Barnett, A. J. Krentz, K. Strojek, J. Sieradzki, F. Azizi, M. Embong, S. Imamoglu, J. Peru i ovß, V. Uli iansky, G. Winkler
http://www3.interscience.wiley.com/cgi-bin/abstract/120125639/ABSTRACT
Pages: 1248-1260
PROCEED: Prospective Obesity Cohort of Economic Evaluation and Determinants: baseline health and healthcare utilization of the US sample*
A. M. Wolf, N. Finer, A. A. Allshouse, K. B. Pendergast, B. H. Sherrill, I. Caterson, J. O. Hill, L. J. Aronne, H. Hauner, C. Radigue, C. Amand, J.-P. Despres
http://www3.interscience.wiley.com/cgi-bin/abstract/121384113/ABSTRACT
Pages: 1261-1265
Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients
H. Masuda, M. Sakamoto, J. Irie, A. Kitaoka, K. Shiono, G. Inoue, K. Atsuda, S. Yamada
http://www3.interscience.wiley.com/cgi-bin/abstract/120125641/ABSTRACT
Pages: 1266-1270
Increase in high molecular weight adiponectin by bariatric surgery-induced weight loss
P. Linscheid, M. Christ-Crain, R. Stoeckli, C. E. Reusch, T. A. Lutz, B. Mⁿller, U. Keller
http://www3.interscience.wiley.com/cgi-bin/abstract/120125643/ABSTRACT
Pages: 1271-1274
Fatty acid synthase inhibitor, C75, blocks resistin-induced increases in lipid accumulation by human macrophages
C. Rae, A. Graham
http://www3.interscience.wiley.com/cgi-bin/abstract/121494350/ABSTRACT
Pages: 1275-1276
Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety
V. Simha, S. Rao, A. Garg
http://www3.interscience.wiley.com/cgi-bin/abstract/121494349/ABSTRACT
Pages: 1135-1156
Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women
Szalat Auryan, Raz Itamar
http://www3.interscience.wiley.com/cgi-bin/abstract/120125640/ABSTRACT
Pages: 1157-1166
The role of renin–angiotensin–aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection
Hussam Abuissa, James O'Keefe Jr
http://www3.interscience.wiley.com/cgi-bin/abstract/120125642/ABSTRACT
Pages: 1167-1177
Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes
P. Raskin
http://www3.interscience.wiley.com/cgi-bin/abstract/120125648/ABSTRACT
Pages: 1178-1185
Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs
M. R. Lankisch, K. C. Ferlinz, J. L. Leahy, W. A. Scherbaum
http://www3.interscience.wiley.com/cgi-bin/abstract/121494348/ABSTRACT
Pages: 1186-1194
Persistence of improvement in insulin sensitivity following a dietary weight loss programme
T. McLaughlin, P. Schweitzer, S. Carter, C.-G. Yen, C. Lamendola, F. Abbasi, G. Reaven
http://www3.interscience.wiley.com/cgi-bin/abstract/120125630/ABSTRACT
Pages: 1195-1203
Weight loss in obese men by caloric restriction and high-dose diazoxide–mediated insulin suppression
G. van Boekel, S. Loves, A. van Sorge, J. Ruinemans-Koerts, T. Rijnders, H. de Boer
http://www3.interscience.wiley.com/cgi-bin/abstract/120125631/ABSTRACT
Pages: 1204-1211
Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients
Y. Miyazaki, R. A. DeFronzo
http://www3.interscience.wiley.com/cgi-bin/abstract/120125633/ABSTRACT
Pages: 1212-1220
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach
L. Xu, C. Dalla Man, B. Charbonnel, G. Meninger, M. J. Davies, D. Williams-Herman, C. Cobelli, P. P. Stein
http://www3.interscience.wiley.com/cgi-bin/abstract/120125634/ABSTRACT
Pages: 1221-1238
Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials
E. Mannucci, M. Monami, C. Lamanna, G. F. Gensini, N. Marchionni
http://www3.interscience.wiley.com/cgi-bin/abstract/120125638/ABSTRACT
Pages: 1239-1247
The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release–based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study)
A. H. Barnett, A. J. Krentz, K. Strojek, J. Sieradzki, F. Azizi, M. Embong, S. Imamoglu, J. Peru i ovß, V. Uli iansky, G. Winkler
http://www3.interscience.wiley.com/cgi-bin/abstract/120125639/ABSTRACT
Pages: 1248-1260
PROCEED: Prospective Obesity Cohort of Economic Evaluation and Determinants: baseline health and healthcare utilization of the US sample*
A. M. Wolf, N. Finer, A. A. Allshouse, K. B. Pendergast, B. H. Sherrill, I. Caterson, J. O. Hill, L. J. Aronne, H. Hauner, C. Radigue, C. Amand, J.-P. Despres
http://www3.interscience.wiley.com/cgi-bin/abstract/121384113/ABSTRACT
Pages: 1261-1265
Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients
H. Masuda, M. Sakamoto, J. Irie, A. Kitaoka, K. Shiono, G. Inoue, K. Atsuda, S. Yamada
http://www3.interscience.wiley.com/cgi-bin/abstract/120125641/ABSTRACT
Pages: 1266-1270
Increase in high molecular weight adiponectin by bariatric surgery-induced weight loss
P. Linscheid, M. Christ-Crain, R. Stoeckli, C. E. Reusch, T. A. Lutz, B. Mⁿller, U. Keller
http://www3.interscience.wiley.com/cgi-bin/abstract/120125643/ABSTRACT
Pages: 1271-1274
Fatty acid synthase inhibitor, C75, blocks resistin-induced increases in lipid accumulation by human macrophages
C. Rae, A. Graham
http://www3.interscience.wiley.com/cgi-bin/abstract/121494350/ABSTRACT
Pages: 1275-1276
Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety
V. Simha, S. Rao, A. Garg
http://www3.interscience.wiley.com/cgi-bin/abstract/121494349/ABSTRACT
Friday, 11 July 2008
Diabetes, Obesity and Metabolism
Review Articles
Current treatment of non-alcoholic fatty liver disease
Mohamed H. Ahmed Christopher D. Byrne
Literature Reviews
Risk factor assessment for new onset diabetes: literature review
George Bakris,Jack Stockert, Mark Molitch, Qian Zhou, Annette Champion, Peter Bacher James Sowers, on behalf of the STAR Investigators
Original Articles
Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-B activation through a phosphoinoside 3-kinaseAkt-dependent pathwayT. Jojima, K. Suzuki, N. Hirama, K. Uchida Y. Hattori
Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?
J. J. Meier, B. Baller, B. A. Menge, B. Gallwitz, W. E. Schmidt M. A. Nauck
Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction
C. L. Oltman, E. P. Davidson, L. J. Coppey, T. L. Kleinschmidt M. A. Yorek
Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients
D. S. H. Bell, G. L. Bakris J. B. McGill
Current treatment of non-alcoholic fatty liver disease
Mohamed H. Ahmed Christopher D. Byrne
Literature Reviews
Risk factor assessment for new onset diabetes: literature review
George Bakris,Jack Stockert, Mark Molitch, Qian Zhou, Annette Champion, Peter Bacher James Sowers, on behalf of the STAR Investigators
Original Articles
Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-B activation through a phosphoinoside 3-kinaseAkt-dependent pathwayT. Jojima, K. Suzuki, N. Hirama, K. Uchida Y. Hattori
Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?
J. J. Meier, B. Baller, B. A. Menge, B. Gallwitz, W. E. Schmidt M. A. Nauck
Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction
C. L. Oltman, E. P. Davidson, L. J. Coppey, T. L. Kleinschmidt M. A. Yorek
Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients
D. S. H. Bell, G. L. Bakris J. B. McGill
Diabetes, Obesity and Metabolism
Volume 10, Issue 7, July 2008
Review Articles
Sudden cardiac death: influence of diabetes
P. M. Spooner
pages 523–532
Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes
D. P. Macfarlane, K. R. Paterson M. Fisher
pages 533–544
Original Articles
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
J. C. N. Chan, R. Scott, J. C. Arjona Ferreira, D. Sheng, E. Gonzalez, M. J. Davies, P. P. Stein, K. D. Kaufman, J. M. Amatruda D. Williams-Herman
pages 545–555
Overnight CSII as supplement to oral antidiabetic drugs in Type 2 diabetes
T. Parkner, M. K. Møller, J. W. Chen, T. Laursen, C. Jørgensen, J. S. Smedegaard, T. Lauritzen J. S. Christiansen
pages 556–563
Pioglitazone attenuates fatty acidinduced oxidative stress and apoptosis in pancreatic -cells
Y. Saitoh, C. Chun-ping, K. Noma, H. Ueno, M. Mizuta M. Nakazato
pages 564–573
Salacia oblonga root decreases cardiac hypertrophy in Zucker diabetic fatty rats: inhibition of cardiac expression of angiotensin II type 1 receptor
T. H. Huang, L. He, Q. Qin, Q. Yang, G. Peng, M. Harada, Y. Qi, J. Yamahara, B. D. Roufogalis Y. Li
pages 574–585
Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabetic subjects
B. Ludvik, M. Hanefeld, G. Pacini
pages 586–592
Research Letters
Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide
M. Horowitz, T. Vilsbøll, M. Zdravkovic, M. Hammer, S. Madsbad
pages 593–596
Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin
R. C. T. Mori, S. M. Hirabara, A. E. Hirata, M. M. Okamoto U. F. Machado
pages 596–600
Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus
I. Brema, M. Hatunic, F. Finucane, N. Burns, J. J. Nolan, D. Haider, M. Wolzt, B. Ludvik
pages 600–602
Review Articles
Sudden cardiac death: influence of diabetes
P. M. Spooner
pages 523–532
Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes
D. P. Macfarlane, K. R. Paterson M. Fisher
pages 533–544
Original Articles
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
J. C. N. Chan, R. Scott, J. C. Arjona Ferreira, D. Sheng, E. Gonzalez, M. J. Davies, P. P. Stein, K. D. Kaufman, J. M. Amatruda D. Williams-Herman
pages 545–555
Overnight CSII as supplement to oral antidiabetic drugs in Type 2 diabetes
T. Parkner, M. K. Møller, J. W. Chen, T. Laursen, C. Jørgensen, J. S. Smedegaard, T. Lauritzen J. S. Christiansen
pages 556–563
Pioglitazone attenuates fatty acidinduced oxidative stress and apoptosis in pancreatic -cells
Y. Saitoh, C. Chun-ping, K. Noma, H. Ueno, M. Mizuta M. Nakazato
pages 564–573
Salacia oblonga root decreases cardiac hypertrophy in Zucker diabetic fatty rats: inhibition of cardiac expression of angiotensin II type 1 receptor
T. H. Huang, L. He, Q. Qin, Q. Yang, G. Peng, M. Harada, Y. Qi, J. Yamahara, B. D. Roufogalis Y. Li
pages 574–585
Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabetic subjects
B. Ludvik, M. Hanefeld, G. Pacini
pages 586–592
Research Letters
Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide
M. Horowitz, T. Vilsbøll, M. Zdravkovic, M. Hammer, S. Madsbad
pages 593–596
Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin
R. C. T. Mori, S. M. Hirabara, A. E. Hirata, M. M. Okamoto U. F. Machado
pages 596–600
Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus
I. Brema, M. Hatunic, F. Finucane, N. Burns, J. J. Nolan, D. Haider, M. Wolzt, B. Ludvik
pages 600–602
Diabetes, Obesity and Metabolism
Volume 10, Issue s2, July 2008
Review Articles
Optimum management of type 2 diabetes timely introduction, optimization and intensification of basal insulin
G. Dailey
pages 5–13
Reaching glycaemic targets while minimizing hypoglycaemia in insulin-treated type 2 diabetes patients
C. Mathieu S. Robbrecht
pages 14–23
Insulin glargine in type 2 diabetes in everyday clinical practice: 7 years experience
S. A. Schreiber
pages 24–34
Insulin therapy in elderly patients with type 2 diabetes: the role of insulin glargine
H. U. Janka
pages 35–41
Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine
M. Davies K. Khunti
pages 42–49
Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine
C. Bradley C. J. B. Gilbride
pages 50–65
The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics
P. Levin
pages 66–75
Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus
D. Raccah
pages 76–82
Beyond insulin replacement: addressing the additional needs of the diabetes patient
G. Dailey
pages 83–97
The publication of this supplement has been supported by an unrestricted educational grant from sanofi-aventis.
Review Articles
Optimum management of type 2 diabetes timely introduction, optimization and intensification of basal insulin
G. Dailey
pages 5–13
Reaching glycaemic targets while minimizing hypoglycaemia in insulin-treated type 2 diabetes patients
C. Mathieu S. Robbrecht
pages 14–23
Insulin glargine in type 2 diabetes in everyday clinical practice: 7 years experience
S. A. Schreiber
pages 24–34
Insulin therapy in elderly patients with type 2 diabetes: the role of insulin glargine
H. U. Janka
pages 35–41
Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine
M. Davies K. Khunti
pages 42–49
Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine
C. Bradley C. J. B. Gilbride
pages 50–65
The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics
P. Levin
pages 66–75
Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus
D. Raccah
pages 76–82
Beyond insulin replacement: addressing the additional needs of the diabetes patient
G. Dailey
pages 83–97
The publication of this supplement has been supported by an unrestricted educational grant from sanofi-aventis.
Diabetes, Obesity and Metabolism
Original Articles
The relationship of glycaemic control and triglycerides in patients with diabetes mellitus: a PreCIS Database Study
M. B. Davidson, T. Hu, Guven Sain, B. Hoar, C. Stevenson B. J. Hoogwerf
Review Articles
Combination statinfibrate therapy: safety aspects
R. Franssen, M. Vergeer, E. S. G. Stroes J. J. P. Kastelein
Original Articles
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
J. C. N. Chan, R. Scott, J. C. Arjona Ferreira, D. Sheng, E. Gonzalez, M. J. Davies, P. P. Stein, K. D. Kaufman, J. M. Amatruda D. Williams-Herman
Family history of diabetes impacts on interactions between minimal model estimates of insulin sensitivity and glucose effectiveness
X. Lopez, C. Bouché, E. Tatro A. B. Goldfine
The relationship of glycaemic control and triglycerides in patients with diabetes mellitus: a PreCIS Database Study
M. B. Davidson, T. Hu, Guven Sain, B. Hoar, C. Stevenson B. J. Hoogwerf
Review Articles
Combination statinfibrate therapy: safety aspects
R. Franssen, M. Vergeer, E. S. G. Stroes J. J. P. Kastelein
Original Articles
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
J. C. N. Chan, R. Scott, J. C. Arjona Ferreira, D. Sheng, E. Gonzalez, M. J. Davies, P. P. Stein, K. D. Kaufman, J. M. Amatruda D. Williams-Herman
Family history of diabetes impacts on interactions between minimal model estimates of insulin sensitivity and glucose effectiveness
X. Lopez, C. Bouché, E. Tatro A. B. Goldfine
Friday, 6 June 2008
Diabetes, Obesity and Metabolism (Online Early articles)
We do not have electronic or print access to this journal. Articles may be avaialble via interlibrary loan. Please contact the library to request articles.
Original Articles
Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials
E. Mannucci, M. Monami, C. Lamanna, G. F. Gensini N. Marchionni
Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats
A. K. Dhalla, M. Santikul, J. W. Chisholm, L. Belardinelli G. M. Reaven
Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study
Y. Gao, X. H. Guo J. A. Vaz PRESENT Study Group
Short Reports
FTY720, a sphingosine-1-phosphate receptor modulator, reverses high-fat dietinduced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice
M. R. Kendall C. J. Hupfeld
Review Articles
Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes
P. Raskin
Original Articles
Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients
H. Masuda, M. Sakamoto, J. Irie, A. Kitaoka, K. Shiono, G. Inoue, K. Atsuda S. Yamada
The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes
Z. Li, Q. Zhang, X. Peng, Y. Wu, Y. Xia X. Liu
Review Articles
Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women
Szalat Auryan Raz Itamar
Original Articles
The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified releasebased regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study)
A. H. Barnett, A. J. Krentz, K. Strojek, J. Sieradzki, F. Azizi, M. Embong, S. Imamoglu, J. Peruiová, V. Uliiansky G. Winkler
All-cause mortality risk predictors in a preventive cardiology clinic cohort-examining diabetes and individual metabolic syndrome criteria: a PRECIS database study
K. B. Doshi, S. R. Kashyap, D. M. Brennan, B. M. Hoar, L. Cho B. J. Hoogwerf
Review Articles
The role of reninangiotensinaldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection
Hussam Abuissa James O’Keefe, Jr
Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation
Eliot A. Brinton
Original Articles
Increase in high molecular weight adiponectin by bariatric surgery-induced weight loss
P. Linscheid, M. Christ-Crain, R. Stoeckli, C. E. Reusch, T. A. Lutz, B. Müller U. Keller
Original Articles
Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials
E. Mannucci, M. Monami, C. Lamanna, G. F. Gensini N. Marchionni
Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats
A. K. Dhalla, M. Santikul, J. W. Chisholm, L. Belardinelli G. M. Reaven
Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study
Y. Gao, X. H. Guo J. A. Vaz PRESENT Study Group
Short Reports
FTY720, a sphingosine-1-phosphate receptor modulator, reverses high-fat dietinduced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice
M. R. Kendall C. J. Hupfeld
Review Articles
Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes
P. Raskin
Original Articles
Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients
H. Masuda, M. Sakamoto, J. Irie, A. Kitaoka, K. Shiono, G. Inoue, K. Atsuda S. Yamada
The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes
Z. Li, Q. Zhang, X. Peng, Y. Wu, Y. Xia X. Liu
Review Articles
Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women
Szalat Auryan Raz Itamar
Original Articles
The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified releasebased regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study)
A. H. Barnett, A. J. Krentz, K. Strojek, J. Sieradzki, F. Azizi, M. Embong, S. Imamoglu, J. Peruiová, V. Uliiansky G. Winkler
All-cause mortality risk predictors in a preventive cardiology clinic cohort-examining diabetes and individual metabolic syndrome criteria: a PRECIS database study
K. B. Doshi, S. R. Kashyap, D. M. Brennan, B. M. Hoar, L. Cho B. J. Hoogwerf
Review Articles
The role of reninangiotensinaldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection
Hussam Abuissa James O’Keefe, Jr
Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation
Eliot A. Brinton
Original Articles
Increase in high molecular weight adiponectin by bariatric surgery-induced weight loss
P. Linscheid, M. Christ-Crain, R. Stoeckli, C. E. Reusch, T. A. Lutz, B. Müller U. Keller
Friday, 23 May 2008
Diabetes, Obesity and Metabolism - Online Early Articles
We do not have direct access to these articles. They may be avaialble via interlibrary loan.
Time of the day for 11 -HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice
M. M. Véniant, C. Hale, R. Komorowski, M. M. Chen, D. J. St Jean, C. Fotsch M. Wang
Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMix®study
H. C. Jang, S. R. Lee J. A. Vaz
Letters to the Editor
The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes
H. Itakura, F. Abbasi, C. Lamendola, M. Basina, G. Reaven
Research Letters
Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus
I. Brema, M. Hatunic, F. Finucane, N. Burns, J. J. Nolan, D. Haider, M. Wolzt, B. Ludvik
Original Articles
Gestational diabetes mellitus and vitamin D deficiency: genetic contribution of CYP27B1 and CYP2R1 polymorphisms
E. Ramos-Lopez, H. Kahles, S. Weber, A. Kukic, M. Penna-Martinez, F. Louwen K. Badenhoop
Weight loss in obese men by caloric restriction and high-dose diazoxidemediated insulin suppression
G. van Boekel, S. Loves, A. van Sorge, J. Ruinemans-Koerts, T. Rijnders H. de Boer
Metformin inhibits intracellular lipid accumulation in the murine pre-adipocyte cell line, 3T3-L1
K. B. Alexandre, A. M. Smit, I. P. Gray N. J. Crowther
Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients
Y. Miyazaki R. A. DeFronzo
Persistence of improvement in insulin sensitivity following a dietary weight loss programme
T. McLaughlin, P. Schweitzer, S. Carter, C.-G. Yen, C. Lamendola, F. Abbasi G. Reaven
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach
L. Xu, C. Dalla Man, B. Charbonnel, G. Meninger, M. J. Davies, D. Williams-Herman, C. Cobelli P. P. Stein
Time of the day for 11 -HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice
M. M. Véniant, C. Hale, R. Komorowski, M. M. Chen, D. J. St Jean, C. Fotsch M. Wang
Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMix®study
H. C. Jang, S. R. Lee J. A. Vaz
Letters to the Editor
The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes
H. Itakura, F. Abbasi, C. Lamendola, M. Basina, G. Reaven
Research Letters
Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus
I. Brema, M. Hatunic, F. Finucane, N. Burns, J. J. Nolan, D. Haider, M. Wolzt, B. Ludvik
Original Articles
Gestational diabetes mellitus and vitamin D deficiency: genetic contribution of CYP27B1 and CYP2R1 polymorphisms
E. Ramos-Lopez, H. Kahles, S. Weber, A. Kukic, M. Penna-Martinez, F. Louwen K. Badenhoop
Weight loss in obese men by caloric restriction and high-dose diazoxidemediated insulin suppression
G. van Boekel, S. Loves, A. van Sorge, J. Ruinemans-Koerts, T. Rijnders H. de Boer
Metformin inhibits intracellular lipid accumulation in the murine pre-adipocyte cell line, 3T3-L1
K. B. Alexandre, A. M. Smit, I. P. Gray N. J. Crowther
Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients
Y. Miyazaki R. A. DeFronzo
Persistence of improvement in insulin sensitivity following a dietary weight loss programme
T. McLaughlin, P. Schweitzer, S. Carter, C.-G. Yen, C. Lamendola, F. Abbasi G. Reaven
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach
L. Xu, C. Dalla Man, B. Charbonnel, G. Meninger, M. J. Davies, D. Williams-Herman, C. Cobelli P. P. Stein
Thursday, 8 May 2008
Diabetes, Obesity and Metabolism Volume 10, Issue 6, June 2008
Review Article
Antiretroviral therapy and the human immunodeficiency virus improved survival but at what cost?
R. A. Bradbury K. Samaras
pages 441–450
Original Articles
Preconditioning and postconditioning: new strategies for cardioprotection
D. J. Hausenloy D. M. Yellon
pages 451–459
Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients
A. Brunani, A. Caumo, S. Graci, G. Castagna, G. Viberti A. Liuzzi
pages 460–467
Sleep-disordered breathing is related to an increased risk for type 2 diabetes in middle-aged men, but not in women the FIN-D2D survey
H. Tuomilehto, M. Peltonen, M. Partinen, J. Seppä, T. Saaristo, E. Korpi-Hyövälti, H. Oksa, J. Saltevo, H. Puolijoki, M. Vanhala J. Tuomilehto
pages 468–475
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome
T. D. Filippatos, E. N. Liberopoulos, M. Kostapanos, I. F. Gazi, E. C. Papavasiliou, D. N. Kiortsis, A. D. Tselepis M. S. Elisaf
pages 476–483
Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study
K. Horvath, G. Bock, W. Regittnig, M. Bodenlenz, A. Wutte, J. Plank, C. Magnes, F. Sinner, S. Fürst-Recktenwald, K. Theobald T. R. Pieber
pages 484–491
Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS
J. H. O’Keefe, H. Abuissa B. Pitt
pages 492–497
Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success
K. Elfhag, N. Finer S. Rössner
pages 498–505
Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects
Haiqinq Dai, Stephanie M. Gustavson, Gregory M. Preston, James D. Eskra, Roberto Calle Boaz Hirshberg
pages 506–513
Letters to the Editor
Impaired glucose tolerance, but not impaired fasting glucose, is associated with retinopathy in Japanese population: the Funagata study
R. Kawasaki, J. J. Wang, T. Y. Wong, T. Kayama H. Yamashita
pages 514–515
Effects of exendin-4 on islets from type 2 diabetes patients
R. Lupi, R. Mancarella, S. Del Guerra, M. Bugliani, S. Del Prato, U. Boggi, F. Mosca, F. Filipponi P. Marchetti
pages 515–519
The long-term impact of ferritin level on treatment and complications of type 2 diabetes
L. Jiang, A. Wang, L. M. Molyneaux, M. I. Constantino D. K. Yue
pages 519–522
Antiretroviral therapy and the human immunodeficiency virus improved survival but at what cost?
R. A. Bradbury K. Samaras
pages 441–450
Original Articles
Preconditioning and postconditioning: new strategies for cardioprotection
D. J. Hausenloy D. M. Yellon
pages 451–459
Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients
A. Brunani, A. Caumo, S. Graci, G. Castagna, G. Viberti A. Liuzzi
pages 460–467
Sleep-disordered breathing is related to an increased risk for type 2 diabetes in middle-aged men, but not in women the FIN-D2D survey
H. Tuomilehto, M. Peltonen, M. Partinen, J. Seppä, T. Saaristo, E. Korpi-Hyövälti, H. Oksa, J. Saltevo, H. Puolijoki, M. Vanhala J. Tuomilehto
pages 468–475
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome
T. D. Filippatos, E. N. Liberopoulos, M. Kostapanos, I. F. Gazi, E. C. Papavasiliou, D. N. Kiortsis, A. D. Tselepis M. S. Elisaf
pages 476–483
Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study
K. Horvath, G. Bock, W. Regittnig, M. Bodenlenz, A. Wutte, J. Plank, C. Magnes, F. Sinner, S. Fürst-Recktenwald, K. Theobald T. R. Pieber
pages 484–491
Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS
J. H. O’Keefe, H. Abuissa B. Pitt
pages 492–497
Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success
K. Elfhag, N. Finer S. Rössner
pages 498–505
Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects
Haiqinq Dai, Stephanie M. Gustavson, Gregory M. Preston, James D. Eskra, Roberto Calle Boaz Hirshberg
pages 506–513
Letters to the Editor
Impaired glucose tolerance, but not impaired fasting glucose, is associated with retinopathy in Japanese population: the Funagata study
R. Kawasaki, J. J. Wang, T. Y. Wong, T. Kayama H. Yamashita
pages 514–515
Effects of exendin-4 on islets from type 2 diabetes patients
R. Lupi, R. Mancarella, S. Del Guerra, M. Bugliani, S. Del Prato, U. Boggi, F. Mosca, F. Filipponi P. Marchetti
pages 515–519
The long-term impact of ferritin level on treatment and complications of type 2 diabetes
L. Jiang, A. Wang, L. M. Molyneaux, M. I. Constantino D. K. Yue
pages 519–522
Subscribe to:
Posts (Atom)
